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Xiaoming Yang, Xuezhong He, Zhengguan Yang, and Esmaiel Jabbari

Abstract: PER2 is a key mammalian circadian clock protein. It also has a tumor suppressive function. Down regulation of
PER2 in the cultured cancer cells accelerates cell proliferation, while overexpression of PER2 inhibits cell growth and induces apoptosis. The Per2 mutant mice have a cancer prone phenotype and an altered DNA damage response. Here we report
that PER2 regulates AKT activity. Cells with down-regulated PER2 expression have prolonged high levels of AKT T308
phosphorylation after growth factor stimulation or DNA damage. PER2 down-regulation delays DNA damage induced Chk2
activation and overrides DNA damage induced apoptosis and cell cycle arrest.
Key words: PER2, AKT, tumor suppressor, DNA damage response.
Résumé : PER2 est une protéine clé de l’horloge circadienne des mammifères. Elle possède également une fonction suppressive des tumeurs. La régulation à la baisse de PER2 chez des cellules cancéreuses en culture accélère la prolifération
alors qu’une surexpression de PER2 inhibe la croissance cellulaire et induit l’apoptose. Des souris Per2 mutantes possèdent
un phénotype de susceptibilité au cancer et une réponse déficiente aux dommages à l’ADN. Nous rapportons ici que PER2
régule l’activité d’AKT. Le haut niveau de phosphorylation d’AKT T308 se maintient plus longtemps après une stimulation
par facteur de croissance ou des dommages à l’ADN chez les cellules où l’expression de PER2 est régulée à la baisse. La régulation à la baisse de PER2 retarde l’activation de Chk2 induite par les dommages à l’ADN, et annule l’apoptose et l’arrêt
du cycle cellulaire induits par les dommages à l’ADN.
Mots‐clés : PER2, AKT, suppresseur de tumeur, réponse au dommage à l’AND.
[Traduit par la Rédaction]

Introduction
In the mammalian clockwork, the Period genes (Per1, 2)
are among the most critical clock genes (Reppert and Weaver
2002). In addition to their roles in controlling mammalian
circadian rhythms, several lines of evidence suggest that the
Period genes also have unique tumor suppressive functions.
For example, Per2 mutant mice not only have a disrupted circadian clock but also show deregulated expressions of cell
cycle control genes (c-Myc, Cyclin D1, Gadd45, Mdm2) and
an abnormal DNA damage response, thus leading to a cancer
prone phenotype (Fu et al. 2002). In human tumor tissues,
PER1 and PER2 are often deregulated. Decreased PER2
RNA levels have been reported in acute leukemias and in
breast tumors (Gery et al. 2005; Winter et al. 2007). Abnormalities in PER2 (and PER1) promoter methylation and
asynchronous protein expression have also been observed in
breast tumors (Chen et al. 2005). Furthermore, it has been reported that a decreased level of PER2 in colorectal tumors
predicts a poor survival (Iacobelli et al. 2008; Oshima et al.
2011; Zeman et al. 2008).
We have shown that Per2 mutant mice develop colonic
polyps and have increased expressions of b-catenin and its

downstream genes (Wood et al. 2008). In addition, introduction of Per2 mutation into ApcMin/+ mice enhances ApcMin/+
associated phenotypes, including increased intestinal polyp
number, anemia, and increased spleen weight (Wood et al.
2008). We have also shown that down-regulation of PER2 increases the growth of cancer cells under normal growth conditions (Wood et al. 2008; Yang et al. 2009). Others have
shown that over expression of PER2 inhibits cell proliferation
and enhances apoptosis in both cultured cancer cells and
transplanted tumors (Gery and Koeffler 2009; Hua et al.
2006, 2007). However, it is unclear how PER2 exerts its tumor suppressive function.
AKT is a key regulator of b-catenin expression and cell
proliferation (Liang and Slingerland 2003; Liao and Hung
2010). AKT inhibits apoptosis and promotes cell growth,
and its overactivation has been implicated in several types of
cancer (Cicenas 2008). After growth factor stimulation, PI3K
generates messenger molecule PIP3, which recruits AKT to
the cell membrane where it is phosphorylated at the T308
site by PDK1 and at the S473 site by mTORC2. The activated AKT phosphorylates its substrates, such as GSK3b at
the S9 site, and this inactivates GSK3b (MacDonald et al.
2009). AKT is also phosphorylated by DNA-PK after DNA
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Fig. 1. PER2 deficiency enhances AKT activation after growth factor stimulation. After HCT116 cells were treated with siRNA (Luciferase
siRNA as control and PER2 siRNA set 1) for 48 h, 100ng/mL of IGF-1 was added to the medium. Samples were taken at the indicated time
points. The relative amounts of PER2 mRNA were determined by real time PCR. The amount in the control cells at time point 0 was set as 1
(A). The amounts of phosphorylated AKT and GSK3b, and total level of PTEN, were examined by specific antibodies. GAPDH was the
loading control (B). Quantification of AKT T308, S473, and GSK3b S9 in the control (gray bars) and PER2 knockdown (empty bars) cells
after IGF-1 stimulation. The levels before the treatment in control cells were set as 1 (C). PER2 was down-regulated by PER2 siRNA set 2 in
HCT116 cells. Cells were treated by 100ng/mL of IGF-1 for the indicated time. The relative amounts of PER2 mRNA were determined by
real time PCR. The amount in the control cells at time point 0 was set as 1 (D). The phosphorylation levels of AKT T308, S473, and GSK3b
S9 were determined by Western blotting (E). Primary MEF cells were isolated from wild type or Per2m/m mice. The genotype was determined
by PCR according to the protocol provided by Jackson Laboratory cells were treated with 100ng/mL of IGF-1 for the indicated time. The
T308 phosphorylated and total AKT were compared (F).

damage (Bozulic et al. 2008). However, AKT overactivation
leads to the inhibition of DNA damage response (Xu et al.
2010). Here we report that PER2 may exert its tumor suppressive function by regulating AKT activity. We demonstrate that PER2-depleted cells have a higher level of
phosphorylated AKT. Furthermore, down-regulation of
PER2 leads to a prolonged AKT activation after growth factor stimulation or DNA damage. Enhanced AKT activity in
PER2 down-regulated cells attenuates doxorubicin induced
DNA damage response and renders cells resistant to chemotherapy drugs.

Materials and methods
Cell Culture and siRNA
HCT116 and SW480 human colon cancer cells obtained
from ATCC (Manassas, Va., USA) were maintained in
RPMI 1640 medium with 10% fetal bovine serum (FBS)
under the condition of 5% CO2 at 37 °C. For siRNA transfection, cells were plated in 6-well plates the day before to
reach 30% confluency by the time of transfection. siRNA oligos (200 pmol) were transfected by Lipofectmine2000 (Invitrogen, Carlsbad, Calif., USA) according to the protocol
provided by the manufacturer. The knockdown efficiency
was examined after 48–72h of incubation by real-time PCR.
The sequences of human PER2 siRNA were designed by
Blockit siRNA Designer (Invitrogene). Sequences of RNA
oligos were as follows:
1. Control (Luciferase): 5′-CGUAACGCGGAAUACUUCGAdTdT-3′ and 5′-UCGAAGUAUUCCGCGUACGdTdT-3′
2. PER2 (Set 1): 5′-GCGUUACCUCUGAGCACAUdTdT-3′
and 5′-AUGUGCUCAGAGGUAACGCdTdT-3′
3. PER2 (Set 2): GCGCUAAGGUCCAGUGAUAdTdT-3′ and
5′-UAUCACUGGACCUUAGCGCdTdT-3′
The sequences for real time PCR quantification of human
PER2 were:
1. PER2 Forward: 5′-CCTCTCCTGGGCTACCTACC-3′
and
2. PER2 Reverse: 5′-CCTCCCAATGATGAAGGAGA-3′
GAPDH was used as a control for real time PCR. The sequences for GAPDH were:
1. GAPDH Forward: 5′-GAGTCAACGGATTTGGTCGT-3′
and
2. GAPDH Reverse: 5′-TTGATTTTGGAGGGATCTCG-3′
MEF cells were generated from the wild type C57BL/6J
and Per2m/m mice (Jackson laboratory, Bar Harbor, Maine,
USA). Per2m/m mice had been backcrossed into C57BL/6J

background for 10 generations. MEF cells were cultured in
DMEM with 10% FBS.
Western blot and antibodies
After 48 h of siRNA transfection, cells were treated with
doxorubicin (Sigma, St. Louis, Mo., USA) for the indicated
time, or treated for 2 h then incubated in the drug free medium. Cells were washed with PBS once, and total protein
extracts were obtained by incubating in NP-40 buffer (0.5%
NP-40, 150 mmol/L NaCl, 50 mmol/L Tris-Cl pH7.4, protease inhibitors). Proteins were then separated by standard
SDS–PAGE and transferred to nitrocellulose membranes.
Antibodies against Chk2 T68, AKT T308, AKT S473,
GSK3b S9, and g–H2AX were from Cell Signaling Technology (Danvers, Mass., USA). Anti-PER2 antibodies were from
Alpha Diagnostic International (San Antonio, Tex., USA).
Other antibodies were from Santa Cruz Biotechnology (Santa
Cruz, Calif., USA). AKT1/2 inhibitor was from Sigma and
dissolved in DMSO. All experiments were repeated at least
3 times. Images were quantified by Image J software (NIH,
USA). Statistic difference was determined by t test and annotated with an asterisk.
Drug sensitivity assay
After siRNA treatment for 48 h, cells were incubated with
the indicated concentration of drug for 24 h. Then cells were
washed with PBS, trypsinized, and seeded in the drug-free
medium. Cells were fixed with methanol and stained with
crystal violet solution after 1 week of incubation. Colonies
were counted.

Results
PER2 deficient cells have enhanced AKT activity
The increased proliferation of PER2 down-regulated cells
prompted us to further investigate the underlying mechanism.
It has been reported that the endothelial cells of Per2 mutant
mice exhibit AKT-dependent senescence (Wang et al. 2008).
Since we have observed that Per2 mutation enhances intestinal tumorigenesis in mice, we used colorectal cancer cells to
investigate the role of PER2 in vitro. Down-regulation of
PER2 in HCT116 cells increased the basal level of T308
phosphorylated AKT (Figs. 1 A and 1B). IGF-1, a growth
factor, acutely stimulated AKT phosphorylation at both T308
and S473 sites (Figs. 1B and 1C). AKT phosphorylations
gradually reduced over the time in the control cells. However,
PER2 knockdown cells had prolonged high levels of AKT
T308 phosphorylation, while the levels of S473 phosphorylated AKT did not differ between the control and PER2
Published by NRC Research Press
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knockdown cells. To determine whether prolonged AKT
T308 phosphorylation caused AKT over-activation, the phosphorylation level of GSK3b at the S9 site was examined. The
phosphorylated GSK3b also remained high in PER2 knockdown cells, suggesting that growth factor induced AKT was
over-activated in PER2 knockdown cells. AKT T308 is phosphorylated by PDK1. The total amount of PDK1 protein did
not change in PER2 down-regulated cells (data not shown).
The expression of PTEN, a negative regulator of PDK1, did
not differ in the control and PER2 down-regulated cells either
(Fig. 1B). We used another set of PER2 siRNA to knockdown PER2 in HCT116 cells (Fig. 1D). Again, in PER2
down-regulated cells, the phosphorylation levels of AKT
T308 and GSK3b S9 were enhanced (Fig. 1E). IGF-1 stimulated AKT phosphorylation was also examined in the wild
type and Per2m/m MEF cells. Per2m/m MEF cells had a prolonged AKT T308 phosphorylation after IGF-1 treatment
(Fig. 1F).
AKT is also an important player in DNA damage response. DNA damage temporarily induces AKT phosphorylation and activation. This process is dependent on mismatch
repair (MMR) genes (Caporali et al. 2008). We tested the kinetics of AKT phosphorylation in HCT116 cells after DNA
double strand breaks were induced by doxorubicin (Dox)
treatment. HCT116 is an MMR deficient cell line, therefore
radiation-induced DNA damage does not cause AKT phosphorylation in HCT116 cells (Xu et al. 2010). When
HCT116 cells were treated with Dox, the level of AKT
T308 phosphorylation in the control cells decreased but remained high in the PER2 down-regulated cells (Figs. 2A–
2C). In fact, AKT T308 phosphorlation slightly increased
after Dox treatment in the PER2 knockdown cells. There
was no significant difference in AKT S473 levels between
the control and PER2 knockdown cells (Figs. 2B and 2C).
We also examined AKT phosphorylation in SW480 cells.
SW480 is an MMR proficient human colon cancer cell line.
As expected, AKT phosphorylation was increased at both
T308 and S473 sites after Dox treatment and their levels
were higher in PER2 knockdown cells (Figs. 2D–2F). After
20 h, AKT S473 phosphorylation dropped to the basal level
in both the control PER2 knockdown cells. AKT T308 phosphorylation in the control cells dropped after 20 h of Dox
treatment but remained elevated in PER2 knockdown cells
(Figs. 2E and 2F).
PER2 down-regulation attenuates DNA damage response
To determine whether PER2 down-regulation had an effect
on the DNA damage response, HCT116 cells were treated
with a low dose of Dox (0.5 µmol/L) for 2 h to induce DNA
double strand breaks (DSBs). In the control cells, Chk2 was
quickly phosphorylated at T68 site, and the Chk2 T68 level
was reduced after 24 h (Figs. 3A and 3B). However, the
DSB-induced Chk2 activation was significantly delayed in
PER2 knockdown cells (Fig. 3B). Proper Chk2 T68 phosphorylation is required for subsequent cell cycle arrest and
DNA damage repair after DSB. In PER2 knockdown cells,
the accumulation of WEE1, a marker of G2/M cell cycle arrest, was inhibited, suggesting that DNA damage-induced cell
cycle arrest was inhibited. Lower levels of cleaved caspase3
in PER2 down-regulated cells indicated that DNA damageinduced apoptosis was attenuated (Figs. 3B and 3C). We
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also treated cells with a prolonged Dox exposure (20 h)
(Figs. 3D and 3E). PER2 depleted cells had a higher level of
phosphorylated Chk2 after a prolonged incubation with Dox
(Fig. 3E). The protein levels of WEE1, CycB1, and p53
were lower in PER2 knockdown cells, indicating that diminished PER2 expression overrode DNA damage-induced cell
cycle arrest (Fig. 3E).
To determine whether the delayed Chk2 T68 phosphorylation in PER2 knockdown cells was dependent on AKT, cells
were treated with AKT1/2 inhibitor for 1 h before the treatment with Dox. Inhibition of AKT activity abolished the
PER2 knockdown effect on Chk2 phosphorylation (Fig. 3G).
There was no difference in Dox induced g-H2AX accumulation in the control and PER2 down-regulated cells, suggesting the absence of PER2 did not affect the cells' ability to
sense the DNA damage (Fig. 3G).
PER2 down-regulated cells are resistant to chemotherapy
drugs
Since PER2 modulated DNA damage response, we tested
whether PER2 depletion altered drug sensitivity of cancer
cells. HCT116 cells with PER2 knocked down were resistant
to DNA damage agents, etoposide, and Dox, compared with
the control, as determined by colony formation assay (Fig. 4).
On the other hand, others have shown that overexpression of
PER2 sensitizes cells to irradiation and chemotherapeutic
drugs (Oda et al. 2009). It is known that AKT over-activation
causes cancer cells resistant to chemotherapy drugs (Henry et
al. 2001; Hirose et al. 2005; Lal et al. 2009). It is likely that
the drug resistant phenotype of PER2 depleted cells might be
due to the enhanced AKT activation after DNA damage.

Discussion
Increasing evidence indicates that the core circadian clock
protein, PER2, has a tumor suppressive function. Overexpression of PER2 causes apoptosis in the cultured cancer cells
(Gery and Koeffler 2009; Hua et al. 2006, 2007). Since
PER2 overexpression disrupts the circadian clock, and expressing a protein to a nonphysiological level may cause unexpected effects, we down-regulated PER2 in cancer cells in
our previous studies and have found that PER2 down-regulation
enhances cancer cell proliferation in vivo and in vitro
(Wood et al. 2008; Yang et al. 2009). Here we report that
PER2 regulates the activity of AKT. PER2 knockdown cells
have a higher basal level of T308 phosphorylated AKT. It
is well-known that AKT promotes cell proliferation. Enhanced AKT activity in PER2 depleted cells may contribute
to the increased cell proliferation.
In PER2 knockdown cells, Chk2 T68 phosphorylation is
delayed and WEE1 accumulation is inhibited after Dox treatment. It is known that medium change may synchronize the
circadian clock in cultured cells. If Chk2 T68 phosphorylation is controlled by the circadian clock then the delayed
Chk2 phosphorylation in PER2 knockdown cells may be due
to the disrupted circadian clock. However we do not think
this is the case, because with or without medium change after
Dox treatment the results are not altered (medium was
changed in Fig. 3B but not in Fig. 3E). In addition, we have
determined that Chk2 T68 phosphorylation does not change
after serum shock in cultured cells. Wee1 transcription is
Published by NRC Research Press
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Fig. 2. Enhanced AKT phosphorylation after DNA damage in PER2 down-regulated cells. After siRNA treatment (Luciferase siRNA or PER2
siRNA set 1), HCT116 cells (A, B, C) and SW480 cells (D, E, F) were treated with 0.5 µmol/L of doxorubicin for the indicated time. The
relative amounts of PER2 mRNA were determined by real time PCR. The amounts in the control cells at time point 0 were set as 1 (A, D).
The amounts of phosphorylated AKT and total AKT were determined by specific antibodies (B, E). Quantification of AKT T308 and AKT
S473 phosphorylation in HCT116 (C) and SW480 (F) (Control, gray bars; Per2 knockdown, empty bars). The amounts in the control cells
before treatment were set as 1.

suppressed by PER/CRY complex (Matsuo et al. 2003).
Knockdown of CRY leads to an elevated expression of
WEE1 (Gauger and Sancar 2005). However, in PER2 knockdown cells, WEE1 accumulation is inhibited after Dox treatment. Therefore, it is unlikely that the altered WEE1
expression in PER2 knockdown cells is due to the disrupted
circadian clock.
AKT overactivation is known to override DNA damageinduced cell cycle arrest and apoptosis in various cells in-

cluding HCT116 (Hirose et al. 2005; Kandel et al. 2002;
Xu et al. 2010). Several studies have shown that AKT prevents the binding of DNA damage mediators, such as
RAD51 and RPA, from forming foci at the damaged DNA
sites (Plo et al. 2008; Xu et al. 2010). Therefore, active
AKT interferes the tranduction of DNA damage signal
from sensors to effectors. PER2 knockdown cells can still
sense the damaged DNA because g-H2AX accumulation
after DNA damage is not affected by the absence of PER2.
Published by NRC Research Press
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Fig. 3. Down-regulation of PER2 alters DNA damage response. HCT116 cells were treated with luciferase siRNA (control) or PER2 siRNA
set 1 for 48 h followed by 0.5 µmol/L doxorubicin treatment for 2 h. Cells were then incubated in the drug-free medium. Samples were taken
at the indicated time points. (NT: no doxorubicin treatment). The relative amounts of PER2 mRNA were determined by real-time PCR. The
amount in the NT control cells was set as 1 (A). Chk2 T68, WEE1, and caspase 3 were detected by specific antibodies. GAPDH was the
loading control (B). Quantification of WEE1 and cleaved caspase 3 in the control (gray bars) and PER2 knockdown cells (empty bars). The
amounts in the control cells without drug treatment were set as 1(C). After 48 h of siRNA treatment, HCT116 cells were incubated with
0.5 µmol/L of doxorubicin for 20 h. The relative amounts of PER2 mRNA were determined by real-time PCR. The amount in control cells at
the time point 0 was set as 1 (D). The expression of proteins determined by Western blotting. GAPDH was the loading control (E). Control or
PER2 knockdown HCT116 cells were treated with AKT1/2 inhibitor (20 µmol/L) for 1 h followed by treatment with 2 µmol/L of doxorubicin
for 2 h. Cells were then incubated in the drug-free medium for the indicated time (NT, no Dox treatment). The relative amounts of PER2
mRNA were determined by real time PCR. The amount in the NT control cells without AKTi treatment was set as 1 (F). The levels of Chk2
T68, total Chk2, and g-H2AX were determined by Western blotting. GAPDH was the loading control (G).
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Fig. 4. Down-regulation of PER2 enhances cancer cell resistance to chemotherapy drugs. After 48 h of siRNA treatment (Luciferase siRNA
or PER2 siRNA set 1), HCT116 cells were treated with the indicated concentrations of doxorubicin (A) or etoposide (B) for 24 h. Numbers of
the colony were counted after 7 days of growth in the drug free medium. Colony number of the control knockdown cells without drug treatment was set as 100%.

Attenuated Chk2 activation in PER2-depleted cells can be
prevented by inhibiting AKT activity, suggesting that PER2
modulates DNA damage response through AKT. It has been
reported that down-regulation of PER1 completely abolishes
DNA damage-induced Chk2 T68 phosphorylation (Gery et
al. 2006). A recent report shows that PER3, another homology of PER2, is also required for Chk2 activation and overexpression of PER3 leads to Chk2 activation without DNA
damage (Im et al. 2010). However, the cancer prone phenotype has never been reported in Per1 or Per3 knockout
mice. In PER2 down-regulated cells, Chk2 T68 phosphorylation is attenuated and delayed but not completely abolished after DNA damage. It is unclear whether PER1,
PER2, and PER3 exert their tumor suppressive functions
through the same pathway. In mammalian circadian clockwork, PER1 and PER2 have similar but nonredundant functions, while PER3 seems not essential for the circadian
clock (Bae et al. 2001; Zheng et al. 2001).
In summary, PER2 may exert its tumor suppressive function by regulating AKT activation. We will further determine
how PER2 regulates AKT activation. PER2 is a transcription
factor. It may also regulate cell proliferation and DNA damage response through other mechanisms. For example, PER2
could directly regulate the expression of genes such as Cyclin
D, C-Myc, and p53. The transcription of these genes is deregulated in Per2 mutant mice (Fu et al. 2002). It is unclear
whether the deregulated expression of these genes is related
to AKT over activation.
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